Member Info for hopeabound

Good article indeed. 'Bidstack has reached an inflection point and the team is leading the charge in building out an open exchange industry standard, enhancing our proprietary programmatic technology and strengthening safety features with Pubguard, our malvertising platform.

We see these as crucial steps to accelerate and scale Bidstack in order to seamlessly bring together game developers and brands. This will enrich the gaming ecosystem to ensure that it continues to flourish and eventually mature into a billion-dollar industry that will create opportunities.'

Drum are doing what they call a 'deep dive' on gaming

'The pandemic has made gaming more popular than ever, and this has not been lost on brands. As Fifa makes more money from virtual football than the real deal and even Gucci launches a gaming strategy, we go on a deep dive, covering everything from the metaverse to mobile gaming as we consider the opportunities open to marketers.'

'https://www.thedrum.com/topics/gaming

Blimey. Didn't expect that. A few days behind but better than not at all!

https://twitter.com/NuformixPlc/status/1400762777547984899

https://nuformix.com/app/uploads/2021/06/NFX-Project-Update-01.06.21.pdf

Well, calls for an update have been answered and positively. Fears that the Oxillo deal were dead have been answered too.

https://www.linkedin.com/company/bidstack/jobs/

2 new jobs added at Bistack that includes a Client Service Manager, which requires: 'Agile approach to work in a high growth environment'.

The other job of interest was a data scientist.

Make of it what you will - but to me, the hires in recent times and roles such as these, do not indicate a failing company but a high growth company, moving from start-up (which it still calls itself in the job description), into a new phase of commercialisation.

ForFXsake - After the placing RNS was the Oxillo announcement - "We are very pleased that Oxilio has exercised its option for NXP001, allowing them to continue the development of NXP001 in oncology. We will now look to finalise the licensing agreement with Oxilio that will provide Nuformix with near term revenue and an opportunity to benefit from the upside of the significant global oncology market.'

My sentiment is along the lines of Mafuta - So, the chairman is a great appoointment. Lots of experience in commericialisation - trade deals.
Joanne remains as a consultant - not gone and has produced the portfolio that is now moving towards a new stage.
Dr Karl Keegan. Not sure what he did actually.

Be interesting to see how the market responds. The new media folk also at the beginning of the month. The chairman joined for a reason.
Other news on deals (Oxillo) and progress on NF002 is required for this to really motor.
Here is hoping.

Covid delayed production of games 'In 2021, 44 percent of respondents said their game has been delayed due to Covid-19, citing a variety of reasons.' https://www.pcgamer.com/uk/44-percent-of-game-developers-say-covid-19-pandemic-has-caused-game-delays/

Sorry Martyh - I didnlt see you had posted.

This has been highlighted in other forums as being inaccurate. It's a forecast of the video game revenue in China (in billions not millions)

If holding shares in Nuformix has taught me one thing, it is to not count my chcikens. Still, canlt help but be hopeful.

Nothing to paint this up as positive. No Ebers, no Asia deal, The Oxillio deal looks dead or why have the placing. Hope I'm wrong. Otherwise, it is somewhere in the future at some unknown point...maybe...hardly an enticing investment. Certainly not what was presented previously. So, let's have an interview from the CEO.

I agree, 3% is still a lot of shares held in this case - such a frustratignly slow process but still, bit by bit they are going.

Almost below the 3% threshold for DT...

Yes, personal reasons are just that. Wish him all the best. He has put the building blocks in place, and time for the CEO to settle in. We have an experienced CEO at the helm. I like the sound of 'weeks.' Goodness knows, we need that.

I wouldn't worry about Roley. He clearly knows nothing about o'wt. He is not knowledgeable on accounting, he knows nothing about the people working at Bidstack and nothing about what the company are doing. Same for the other one who claims to know why Wise has moved. He knows nothing as to why that is the case, so ignore it or report it.

Until now, Nuformix have failed to deliver. It is clear however, that a new team is in place, which I hope, will start to transform the company from it's current status. It has been frustrating, of that there is no doubt but 2021 is looking more promising than where we were last year with al the resignations and what not. Will look forward to the developments that arise over the first half of next year.

Also with immediate effect and for its 'near-term strategic priorities.

Majorboy. Er...no!

Gerard Brandon (CEO) said on here back in July:

'£3m debt facility

No dilution to shareholders at a discount

Funding aligned to our growth pace and COVID-19 real-time sensor project well into 2021

Initial drawdown is £1.5m

No loan repayments until 2021

Lender can convert £950,000 at 2.97p

Warrants of 25% of drawdown (£375,000) exercisable at 30% Premium to share price on the date of grant',

Sorry for the loss Halespur. Let us hope that Nuformix comes good for patients that of course in turn helps our investment. I am sure the company are trying their best to acheive both aims.